Ductal Carcinoma in Situ malady

Wikipedia: Mammary ductal carcinoma is the most common type of breast cancer in women. It comes in two forms:...⁴⁴ more...

MalaCards: Ductal Carcinoma in Situ, also known as ductal breast carcinoma, is related to breast carcinoma in situ and breast cancer. An important gene associated with Ductal Carcinoma in Situ is TAS2R64P (taste receptor, type 2, member 64 pseudogene), and among its related pathways are Pancreatic cancer and Signal transduction_PTEN pathway. The compounds vincristine and fibrinogen have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, breast and monocytes, and related mouse phenotypes are respiratory system and craniofacial.

ductal carcinoma in situ 6 8 ductal breast carcinoma 43

Diseases related to ductal carcinoma in situ by text searches and GeneDecks gene sharing:

(show top 50)    (show all 875)

id	Related Disease	Score	Top Affiliating Genes
1	breast carcinoma in situ	32.1	BRCA1, BRCA2, CDH1, ERBB2, TP53, KRT19
2	breast cancer	31.7	BRCA1, BRCA2, VEGFA, BCL2, MSH6, MMP13
3	lobular neoplasia	31.6	MUC1, CDH1, ESR1, ESR2
4	cribriform carcinoma	31.2	KIT, ESR1, TP63, PGR
5	carcinoma	24.7	PIP, PIK3CA, KIT, PCNA, RB1, SERPINE1
6	pancreatic ductal adenocarcinoma	24.4	VIM, VEGFA, BIRC5, BCL2, BCL2L1, CHGA
7	hypoxia	18.9	PIK3CA, KIT, PCNA, RB1, SERPINE1, BRCA1
8	breast carcinoma	17.9	PIP, PIK3CA, KIT, PCNA, RB1, SERPINE1
9	fibrosis	17.1	PIK3CA, KIT, PCNA, SERPINE1, VIM, BRCA1
10	glassy cell carcinoma of the cervix	14.0	ESR1, ERBB2, PGR
11	progesterone-receptor negative breast cancer	14.0	RASSF1, ESR1, ERBB2, EGFR, PGR
12	hereditary diffuse gastric cancer	14.0	CDH3, CDH1, ERBB2
13	cystic fibrosis	14.0	PIP, RARA, ESR1, CTSD, PGR
14	fallopian tube carcinoma	14.0	BRCA1, BRCA2, ERBB2
15	hidradenitis suppurativa	14.0	PIP, HSD17B13, PTHLH, SRD5A1, KRT14
16	horseshoe kidney	14.0	MME, CA9, ACTC1, SYP
17	mammary paget's disease	13.9	AR, ERBB2, KRT14, EGFR, PGR
18	apocrine adenocarcinoma	13.9	PIP, PTHLH, PGR
19	adrenal carcinoma	13.9	MKI67, CCNB1, CCND1, SYP
20	hidradenitis	13.9	PIP, MUC1, HSD17B13, PTHLH, SRD5A1, KRT14
21	catamenial pneumothorax	13.9	MUC16, ESR1, PGR
22	mixed epithelial stromal tumour	13.9	MME, CYP19A1, PGR
23	sclerosing adenosis of breast	13.9	MKI67, ERBB2, TP53
24	estrogen resistance	13.9	CCND1, AKT1, ESR1, CYP19A1, TFF1
25	androgenetic alopecia	13.9	AR, CYP19A1, SRD5A1, STS
26	papillary serous adenocarcinoma	13.9	MUC16, ERBB2, PGR
27	bullous pemphigoid	13.9	PLAU, PLAUR, KRT5, KRT14, DST
28	gender identity disorder	13.9	AR, ESR1, ESR2, CYP19A1, PGR
29	serous cystadenocarcinoma	13.9	MUC16, MMP14, TYMP
30	ovarian cancer	13.9	BRCA1, MUC16, ERBB2, PGR
31	androgen insensitivity syndrome, partial	13.8	AR, CYP19A1, SRD5A1
32	progesterone resistance	13.8	ESR1, ESR2, PGR
33	familial medullary thyroid carcinoma	13.8	CHGA, MKI67, PTHLH, COPS5, SYP
34	vulva cancer	13.8	PIP, TP53, EGFR
35	invasive bladder transitional cell carcinoma	13.8	CDKN1A, IFI27, ERBB2, TP53, EGFR
36	signet ring basal cell carcinoma	13.8	PIP, CHGA, CDH1
37	primary pigmented nodular adrenocortical disease	13.8	CHGA, ESR1, ESR2, CYP19A1, SYP, PGR
38	inflammatory breast carcinoma	13.8	CDH1, MDM2, ESR1, ERBB2, TFF1
39	pneumothorax	13.8	MUC1, MUC16, ESR1, ACTC1, PGR
40	hidradenocarcinoma	13.8	ESR1, ERBB2, TP53, TP63, KRT5, EGFR
41	diffuse gastric cancer	13.8	CDH3, CDH1, GSTP1, ERBB2
42	centrocytic lymphoma	13.8	BCL2, MKI67, CCND1
43	male pseudohermaphroditism due to defective lh	13.8	AR, HSD17B13, SRD5A1, WT1
44	meningioma	13.8	PCNA, MKI67, ESR1, PGR
45	refractive error	13.8	MMP13, MMP14, MMP9, ACTC1, TIMP2, TIMP4
46	bile duct adenoma	13.8	ERBB2, TP53, TP63, KRT19
47	ameloblastic carcinoma	13.8	MUC1, MKI67, TP63
48	gynecomastia	13.8	BRCA1, BRCA2, MUC1, AR, APOD, ESR1
49	transsexualism	13.8	AR, ESR1, ESR2, CYP19A1, PGR
50	cavernous hemangioma of face	13.8	MKI67, TP63, KRT19, ACTC1

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to ductal carcinoma in situ:

²²

MGI Mouse Phenotypes related to ductal carcinoma in situ:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.5	BRCA1, PAX6, FOXC1, GSN, MEF2C, TP63
2	craniofacial phenotype	MP:0005382	9.9	KIT, PAX6, FOXC1, FGFR2, MEF2C, KRT5
3	endocrine/exocrine gland phenotype	MP:0005379	9.2	BRCA1, BRCA2, CDKN1B, CDH3, GSN, FGFR2
4	other phenotype	MP:0005395	9.0	RARA, CDKN2A, MME, MMP14, FOXC1, ESR2
5	pigmentation phenotype	MP:0001186	8.5	KIT, RB1, BRCA1, PAX6, BCL2, CDKN1B
6	no phenotypic analysis	MP:0003012	8.2	PCNA, RB1, VEGFA, MUC1, CDKN1B, CD44
7	hematopoietic system phenotype	MP:0005397	8.1	KIT, PCNA, BRCA1, BRCA2, BNIP3, BNIP3L
8	embryogenesis phenotype	MP:0005380	8.0	PIK3CA, KIT, VIM, BRCA1, BRCA2, BIRC5
9	renal/urinary system phenotype	MP:0005367	7.9	KIT, BRCA1, RARA, CLDN7, PAX6, BCL2
10	liver/biliary system phenotype	MP:0005370	7.8	KIT, VEGFA, FOXC1, AR, IFNG, AKT1
11	normal phenotype	MP:0002873	7.4	BRCA1, BRCA2, VEGFA, RARA, PAX5, PAX6
12	limbs/digits/tail phenotype	MP:0005371	7.3	KIT, RB1, BRCA1, BRCA2, VEGFA, RARA
13	adipose tissue phenotype	MP:0005375	7.3	PIK3CA, RB1, SERPINE1, BRCA1, BCL2, CDKN1A
14	hearing/vestibular/ear phenotype	MP:0005377	7.3	KIT, RB1, RARA, PAX5, PAX6, BCL2
15	immune system phenotype	MP:0005387	7.0	KIT, VIM, BRCA1, BRCA2, BNIP3L, RARA
16	reproductive system phenotype	MP:0005389	6.6	PIK3CA, BRCA1, BRCA2, VEGFA, RARA, PAX6
17	nervous system phenotype	MP:0003631	6.3	KIT, RB1, BRCA1, RARA, PAX5, PAX6
18	skeleton phenotype	MP:0005390	6.2	KIT, RB1, BRCA1, BRCA2, VEGFA, RARA
19	behavior/neurological phenotype	MP:0005386	6.0	PIK3CA, KIT, RB1, VIM, BRCA2, PAX5
20	integument phenotype	MP:0010771	5.5	KIT, RB1, BRCA1, BRCA2, CLDN7, PAX6
21	growth/size phenotype	MP:0005378	5.0	PIK3CA, KIT, RB1, SERPINE1, BRCA1, BRCA2
22	mortality/aging	MP:0010768	5.0	PIK3CA, RB1, SERPINE1, BRCA1, BRCA2, VEGFA
23	vision/eye phenotype	MP:0005391	4.6	PIK3CA, KIT, RB1, VIM, VEGFA, RARA
24	muscle phenotype	MP:0005369	4.2	PIK3CA, KIT, RB1, VIM, BRCA1, VEGFA
25	digestive/alimentary phenotype	MP:0005381	3.9	KIT, RB1, BRCA1, BRCA2, VEGFA, RARA
26	tumorigenesis	MP:0002006	3.7	PIK3CA, KIT, RB1, SERPINE1, BRCA1, BRCA2
27	cardiovascular system phenotype	MP:0005385	2.8	PIK3CA, KIT, RB1, SERPINE1, VIM, BRCA1
28	cellular phenotype	MP:0005384	2.1	PIK3CA, KIT, PCNA, RB1, VIM, BRCA1
29	homeostasis/metabolism phenotype	MP:0005376	1.9	PIK3CA, KIT, RB1, SERPINE1, VIM, BRCA1

Articles related to ductal carcinoma in situ:

(show top 50)    (show all 177)

id	Title	Authors	Year	Affiliating Genes
1	HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extens ive DCIS component. (21095069)	Liao N.... Wu Y.L.	2011	ERBB2
2	Clinicopathologic correlation of cancer stem cell mar kers CD44, CD24, VEGF and HIF-1I+ in ductal carcinoma in situ and invasive ducta l carcinoma of breast: an immunohistochemistry-based pilot study. (21802218)	Wang Z.... Xie F.	2011	VEGFA, HIF1A, CD44
3	Biomarker expression and risk of subsequent tumors af ter initial ductal carcinoma in situ diagnosis. (20427430)	Kerlikowske K.... Tlsty T.D.	2010	PTGS2, CDKN2A, MKI67
4	Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. (19950406)	Collins L.C.... Habel L.A.	2009	PGR, ESR1
5	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. (19444935)	Miki Y.... Sasanoa H.	2009	CYP19A1, SRD5A1
6	Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. (18657193)	Kawasaki T.... Katoh R.	2008	SYP, CHGA
7	Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. (18837981)	Okumura Y.... Iwase H.	2008	FGFR2, BAX, BIRC5
8	Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. (17290405)	Nielsen B.S.... K.	2007	PLAU, MMP13, PLAUR
9	Plasminogen activator system localization in 60 cases of ductal carcinoma in situ. (17701256)	Hurd T.C.... Gibbs J.F.	2007	PLAU, PLAUR
10	CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. (16828238)	Bircan S.... Candir O.	2006	PGR
11	Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. (16528377)	Bryan B.B.... Collins L.C.	2006	EGFR
12	Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. (16941011)	Dabbs D.J.... Bhargava R.	2006	EGFR, VIM, KRT14
13	Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. (17060931)	Wilson G.R.... Bundred N.J.	2006	SRC, ERBB2, CSK
14	Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. (16707453)	Schuetz C.S.... Neubauer H.J.	2006	MEF2C, DST
15	Impact of estrogen receptor expression and other clin icopathologic features on tamoxifen use in ductal carcinoma in situ. (16596655)	Hird R.B.... Newman L.	2006	ESR1
16	Ductal carcinoma in situ of the breast with osteoclas t-like giant cells. (16613333)	Krishnan C.... Longacre T.A.	2006	VEGFA
17	Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. (16638874)	Namba R.... Gregg J.P.	2006	PIK3CA
18	Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. (15788662)	Barnes N.L.... Bundred N.J.	2005	ERBB2, ERBB4, ERBB3
19	Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. (15722788)	Siziopikou K.P.... Khan S.	2005	ERBB2, BCL2L1
20	Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. (15642160)	Vestey S.B.... Winters Z.E.	2005	IGFBP3
21	Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (15728167)	Claus E.B.... Carter D.	2005	BRCA1, BRCA2
22	Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. (15737842)	Maxhimer J.B.... Xu X.	2005	HPSE
23	Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. (15736216)	Barnes N.L.... Bundred N.J.	2005	ESR1
24	Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. (15564794)	Lightfoot H.M.... Cance W.G.	2004	PTK2
25	Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. (15010825)	Liu J.... Sahin A.	2004	TERT
26	COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. (14735188)	Boland G.P.... Bundred N.J.	2004	ERBB2, ESR1, PTGS2
27	Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? (12704442)	Ribeiro-Silva A.... Zucoloto S.	2003	TP63, ACTC1
28	Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. (12527916)	Honorio S.... Latif F.	2003	RASSF1
29	Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. (12628841)	Provenzano E.... Armes J.E.	2003	ESR1
30	Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. (14648660)	Sowter H.M.... Harris A.L.	2003	BNIP3L, BNIP3
31	Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. (14534730)	Schmid B.C.... Zeillinger R.	2003	MUC1
32	Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. (12401835)	Kasami M.... Page D.L.	2002	PGR
33	Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast. (12168892)	Lebrecht A.... Koelbl H.	2002	PGR, ESR1
34	The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. (12481013)	Latta E.K.... O'Malley F.P.	2002	ERBB2
35	Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. (12168077)	Tan P.H.... Bay B.H.	2002	TP53, PGR, ESR1
36	Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. (11506959)	Ringberg A.... FernAP M.	2001	BCL2
37	Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. (11342981)	Iwase H.... Kobayashi S.	2001	ERBB2, TP53, ESR1
38	Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. (11758715)	Suo Z.... Nesland J.M.	2001	ERBB2, EGFR, ERBB3
39	In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. (11147584)	Ho G.H.... Van Zee K.J.	2000	ERBB2, TP53
40	Sequence-ready contig for the 1.4-cM ductal carcinoma in situ loss of heterozygosity region on chromosome 8p22-p23. (10458905)	Wang J.C.... Donis-Keller H.	1999	MTMR9
41	c-erbB-3 protein expression in ductal carcinoma in situ of the breast. (9470844)	Bobrow L.G.... Gullick W.J.	1997	ERBB3
42	High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. (8968105)	Man S.... Brook J.D.	1996	FHIT
43	Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. (8932338)	Munn K.E.... Varley J.M.	1996	TP53
44	Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. (8758245)	Perin T.... Carbone A.	1996	ERBB2, TP53, CTSD
45	Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. (7562248)	Bobrow L.G.... Millis R.R.	1995	TP53, PGR
46	p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. (8041120)	O'Malley F.P.... Page D.L.	1994	TP53
47	Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. (8100443)	Poller D.N.... Ellis I.O.	1993	ESR1
48	Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. (1317202)	Walker R.A.... Dearing S.J.	1992	TGFB1
49	Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. (2170971)	Lodato R.F.... LiVolsi V.A.	1990	ERBB2
50	Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. (1977679)	Bartkova J.... Gullick W.J.	1990	ERBB2

Genes related to ductal carcinoma in situ according to GeneCards:

(show top 50)    (show all 120)

id	Symbol	Description	Score	GeneCards Section Context
1	TAS2R64P	taste receptor, type 2, member 64 pseudogene	11.0	Publications
2	TMEM158	transmembrane protein 158 (gene/pseudogene)	11.0	Publications
3	CLDN7	claudin 7	11.0	Publications, Expressions
4	TIMP4	TIMP metallopeptidase inhibitor 4	11.0	Publications
5	KLK10	kallikrein-related peptidase 10	11.0	Publications
6	SAGE1	sarcoma antigen 1	11.0	Publications
7	CD24	CD24 molecule	11.0	Publications
8	S100A7	S100 calcium binding protein A7	11.0	Publications
9	PIP	prolactin-induced protein	11.0	Publications
10	MMP26	matrix metallopeptidase 26	11.0	Publications
11	MTMR9	myotubularin related protein 9	11.0	Publications
12	BNIP3L	BCL2/adenovirus E1B 19kDa interacting protein 3-like	11.0	Publications
13	FOXC1	forkhead box C1	11.0	Publications
14	HSD17B13	hydroxysteroid (17-beta) dehydrogenase 13	11.0	Publications
15	KRT14	keratin 14	11.0	Publications
16	TFF1	trefoil factor 1	11.0	Publications
17	ACTC1	actin, alpha, cardiac muscle 1	11.0	Publications
18	KRT5	keratin 5	11.0	Publications
19	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	11.0	Publications
20	CDH3	cadherin 3, type 1, P-cadherin (placental)	11.0	Publications
21	BNIP3	BCL2/adenovirus E1B 19kDa interacting protein 3	11.0	Publications
22	APOD	apolipoprotein D	11.0	Publications
23	CA12	carbonic anhydrase XII	11.0	Publications
24	TNK2	tyrosine kinase, non-receptor, 2	11.0	Expressions
25	PGR	progesterone receptor	11.0	Publications
26	HPSE	heparanase	11.0	Publications
27	CA9	carbonic anhydrase IX	11.0	Publications
28	ERBB3	v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)	11.0	Publications
29	PAX6	paired box 6	11.0	Publications
30	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	11.0	Publications
31	RARS	arginyl-tRNA synthetase	11.0	Publications
32	MMP13	matrix metallopeptidase 13 (collagenase 3)	11.0	Publications
33	S100A9	S100 calcium binding protein A9	11.0	Publications
34	IGFBP7	insulin-like growth factor binding protein 7	11.0	Publications
35	TYMP	thymidine phosphorylase	11.0	Publications
36	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)	11.0	Publications
37	MYH11	myosin, heavy chain 11, smooth muscle	11.0	Publications
38	BRCA2	breast cancer 2, early onset	11.0	Publications
39	KPNA2	karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	11.0	Publications
40	COPS5	COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis)	11.0	Publications
41	CCNA2	cyclin A2	11.0	Publications
42	CCNB1	cyclin B1	11.0	Publications
43	PLAUR	plasminogen activator, urokinase receptor	11.0	Publications
44	KRT19	keratin 19	11.0	Publications
45	TIMP2	TIMP metallopeptidase inhibitor 2	11.0	Publications
46	MEF2C	myocyte enhancer factor 2C	11.0	Publications
47	MME	membrane metallo-endopeptidase	11.0	Publications
48	MMP14	matrix metallopeptidase 14 (membrane-inserted)	11.0	Publications
49	MKI67	antigen identified by monoclonal antibody Ki-67	11.0	Publications
50	PAX5	paired box 5	11.0	Publications

Pathways related to ductal carcinoma in situ according to GeneDecks:

(show top 50)    (show all 179)

id	Pathway	Score	Top Affiliating Genes
1	Pancreatic cancer20	10.9	BRCA2
2	Signal transduction_PTEN pathway41	10.7	PCNA
3	Colorectal cancer20	10.3	MSH6, TGFB1
4	Translation Non-genomic (rapid) action of Androgen Receptor10	10.1	EGFR, SRD5A1, SRC, PTEN, ERBB2, AR
5	Cell adhesion PLAU signaling10	10.1	EGFR, PLAUR, PLAU, PTK2, SERPINE1, PIK3CA
6	p53 signaling pathway20	9.6	THBS1, SERPINE1, BAX, CDKN1A, MDM2, CCNB1
7	Cell adhesion_ECM remodeling41	9.6	PLAUR, EGFR, TIMP2, PLAU, SPARC, SERPINE1
8	Cell adhesion ECM remodeling10	9.6	SPARC, PLAU, PLAUR, TIMP2, ERBB4, MMP9
9	Glioblastoma Multiforme36	9.6	E2F1, EGFR, PTEN, TP53, AKT1, CDKN1B
10	Development Ligand-independent activation of ESR1 and ESR210	9.6	ESR1, ERBB3, PIK3CA, EGF, ESR2, EGFR
11	G1-S Phase Transition36	9.5	CDKN2A, TP53, E2F1, TGFB1, CCND1, CCNA2
12	Development_Ligand-independent activation of ESR1 and ESR241	9.5	PIK3CA, TFF1, AKT1, CCND1, ERBB2, ERBB3
13	p53 Signaling36	9.5	BCL2, E2F1, THBS1, HIF1A, BRCA1, BAX
14	Celecoxib Pathway, Pharmacodynamics34	9.4	PTGS2, AKT1, CA12, CA9, MMP9, CDKN1B
15	Cyclins and Cell Cycle Regulation36	9.4	E2F1, TGFB1, PPP2R2B, TP53, CCND1, CCNB1
16	Signal transduction_AKT signaling41	9.4	BAX, PIK3CA, PCNA, BCL2L1, CDKN1A, CDKN1B
17	Akt Signaling36	9.4	CXCR4, TIMP4, PTK2, ERBB4, ERBB3, AKT1
18	Signal transduction PTEN pathway10	9.3	SRC, CDKN1A, PCNA, EGF, AKT1, PIK3CA
19	Cell adhesion_PLAU signaling41	9.2	AKT1, STAT1, EGFR, EGF, PLAU, SRC
20	Endometrial cancer20	9.2	EGF, EGFR, PTEN, TP53, ERBB2, AKT1
21	EGF Pathway36	9.1	CSK, STAT1, EGFR, SRC, CDH1, PTK2
22	Non-small cell lung cancer20	9.1	CDKN2A, FHIT, RB1, E2F1, RASSF1, AKT1
23	Breast Cancer Regulation by Stathmin136	9.1	CCNB1, ERBB4, ERBB2, PPP2R2B, EGF, EGFR
24	Cell cycle20	9.1	RB1, CDKN1B, CDKN1A, CCNB1, E2F1, CCND1
25	Chronic myeloid leukemia20	9.0	CDKN1B, E2F1, TGFB1, TP53, AKT1, CCND1
26	Cell Cycle / Checkpoint Control3	9.0	PCNA, RB1, BRCA1, BRCA2, MDM2, CCNB1
27	Translation_Non-genomic (rapid) action of Androgen Receptor41	9.0	PTEN, SRC, MDM2, EGF, EGFR, PIK3CA
28	Small cell lung cancer20	8.9	PTGS2, PIK3CA, PTK2, PTEN, TP53, E2F1
29	Angiogenesis3	8.8	CA9, ENG, TYMP, FGFR2, MMP9, TIMP2
30	Glioma20	8.8	MDM2, CCND1, AKT1, TP53, PTEN, CDKN1A
31	Development_EGFR signaling pathway41	8.8	EGFR, EGF, SRC, PTK2, ERBB2, AKT1
32	Melanoma20	8.7	E2F1, EGFR, EGF, PTEN, TP53, AKT1
33	ErbB signaling pathway20	8.7	ERBB4, EGFR, EGF, SRC, PTK2, ERBB2
34	Bladder cancer20	8.6	E2F1, ERBB2, CCND1, MDM2, MMP9, CDH1
35	eNOS Signaling36	8.2	ESR2, ERBB2, EGFR, TIMP2, TIMP4, ERBB4
36	Rho Family GTPases36	8.2	CDH3, CDH1, FGFR2, ERBB3, ERBB4, ERBB2
37	Mitochondrial Apoptosis36	8.1	KIT, BCL2, TIMP4, BCL2L1, BAX, CDKN2A
38	p53 Mediated Apoptosis36	8.1	EGFR, TIMP2, TIMP4, TGFB1, EGF, PTEN
39	Prostate cancer20	8.1	CCND1, MDM2, FGFR2, GSTP1, AR, CDKN1B
40	Cellular Apoptosis Pathway36	8.0	KIT, BCL2L1, TIMP4, BAX, BCL2, MDM2
41	Colorectal Cancer Metastasis36	7.7	BIRC5, EGFR, TGFB1, STAT1, EGF, SRC
42	Estrogen Pathway36	7.6	TIMP2, SRC, ERBB2, ERBB3, ESR2, ESR1
43	p38 Signaling36	7.6	ERBB4, ERBB3, BAX, MEF2C, ERBB2, TP53
44	ERK Signaling36	7.6	STAT1, TGFB1, TIMP4, TIMP2, PIP, EGF
45	ILK Signaling36	7.5	EGFR, EGF, PPP2R2B, CDH13, CDH1, FGFR2
46	JAK-STAT Pathway36	7.3	KIT, TIMP4, CXCR4, STAT1, IFNG, TGFB1
47	GSK3 Signaling36	7.3	ERBB4, TGFB1, EGF, TIMP2, EGFR, TIMP4
48	Pancreatic Adenocarcinoma36	6.5	E2F1, STAT1, TGFB1, TP53, PTGS2, SRC
49	Molecular Mechanisms of Cancer36	6.5	BAX, BCL2L1, BCL2, RARA, BRCA1, RB1
50	Pathways in cancer20	5.9	RARA, VEGFA, BRCA2, RB1, PIK3CA, RASSF1

Compounds related to ductal carcinoma in situ according to GeneDecks:

(show top 50)    (show all 458)

id	Compound	Score	Top Affiliating Genes
1	vincristine32 34 9 9	13.4	KIT, PTHLH
2	fibrinogen32	10.2	PIP, SERPINE1, S100A9, MMP13, MMP14, MMP26
3	lysine32	9.7	BRCA1, CDKN1B, MME, CCNB1, CCNA2, ERBB4
4	h2o232	9.6	BRCA1, BRCA2, MUC16, S100A9, MME, FGFR2
5	letrozole32 42 9 9	12.6	MKI67, AR, IGFBP3, ESR1, ESR2, ERBB2
6	hyaluronic acid32 18	10.4	VIM, MUC1, MUC16, CD44, CDH1, MMP13
7	sulindac32 9 9	11.3	PCNA, BIRC5, BCL2, BCL2L1, BAX, CDKN1A
8	p0000132	9.3	SERPINE1, BIRC5, CDKN1B, CDKN2A, CD44, CDH1
9	olomoucine32 42 9 9	12.2	PCNA, RB1, BCL2, BAX, CDKN1A, CDKN2A
10	2-methoxyestradiol32 18	10.2	PCNA, PAX5, BCL2, BCL2L1, BAX, CDKN1A
11	folate32	9.1	VIM, BRCA1, BRCA2, RARA, RASSF1, MUC1
12	fulvestrant32 34 9 9	12.1	PCNA, AR, IGFBP3, ESR1, ESR2, ERBB2
13	chloramphenicol32 9 9	11.1	SERPINE1, VIM, RARA, RARS, CHGA, MUC1
14	hematoxylin32	9.0	KIT, PCNA, VIM, CHGA, MUC1, MUC16
15	arginine32	9.0	PIK3CA, RARA, RARS, PAX6, CHGA, CD44
16	tetracycline32 9 9	10.9	RB1, CDKN2A, MMP13, MMP14, MMP9, IFI27
17	noxa32	8.7	BIRC5, BCL2, BCL2L1, BAX, CDKN1A, MDM2
18	ag 147832	8.7	PIK3CA, SERPINE1, CDKN1B, MMP14, MMP9, CCND1
19	gnrh32	8.7	SERPINE1, VIM, MME, MKI67, AR, IGFBP3
20	pge232	8.6	CDH1, MME, MMP13, AR, ERBB4, PTK2
21	celecoxib32 42 34 9 18 9	13.5	PCNA, VEGFA, BIRC5, BCL2, BAX, CDKN1A
22	ly29400232	8.4	PIK3CA, VEGFA, RARA, CDKN1B, CD44, CDH1
23	lactacystin32	8.4	BRCA1, BIRC5, BCL2, BCL2L1, CDKN1A, CDKN1B
24	herbimycin a32 42	9.4	CDH1, MMP13, MMP14, MMP9, CCNA2, IFNG
25	vitamin d32	8.1	SERPINE1, VIM, RARA, RARS, PAX5, CHGA
26	cytarabine32 34 9 9	11.0	KIT, PCNA, RB1, VIM, BCL2, BCL2L1
27	rapamycin32 42	8.6	KIT, RB1, VIM, VEGFA, AR, MDM2
28	alanine32	7.5	PCNA, BRCA1, RARA, RASSF1, BIRC5, PAX6
29	carboplatin32 34 9 9	10.4	RB1, BRCA1, VEGFA, BCL2, CHGA, MUC16
30	glutamate32	7.4	PIK3CA, PCNA, VIM, CDKN1B, CDH1, MME
31	adenylate32	7.3	PIK3CA, SERPINE1, VIM, CHGA, CD44, CDH1
32	12-o-tetradecanoylphorbol 13-acetate32	7.3	RB1, RARA, RARS, CDKN1A, CDKN1B, CD44
33	lactate32	7.2	PIK3CA, KIT, PCNA, VIM, BNIP3, BIRC5
34	sb 20358032 42	8.0	RB1, VIM, VEGFA, BNIP3, BIRC5, BCL2
35	oxygen32 18	7.9	RB1, BRCA1, BIRC5, PAX6, BCL2, BCL2L1
36	agar32	6.9	PIK3CA, RB1, VIM, BRCA1, RARA, RASSF1
37	phosphoinositide32	6.9	PIK3CA, KIT, VIM, RARA, BIRC5, BCL2L1
38	5-aza-2deoxycytidine32	6.4	PCNA, VIM, BRCA1, BNIP3, RASSF1, CDKN1A
39	thymidylate32	6.4	PCNA, RB1, VIM, BRCA1, VEGFA, BIRC5
40	cysteine32	6.0	PCNA, BRCA1, RARA, BCL2L1, MUC1, CDKN2A
41	matrigel32	5.9	PIK3CA, RB1, SERPINE1, VIM, BRCA2, VEGFA
42	gefitinib32 34 9 9	8.8	PIK3CA, KIT, VIM, VEGFA, BIRC5, BCL2L1
43	etoposide32 42 9 9	8.6	PIK3CA, PCNA, RB1, RARA, BIRC5, BCL2
44	progesterone32 42 9 18 9	8.6	PIP, PIK3CA, KIT, PCNA, RB1, BRCA1
45	doxorubicin32 34 9 9	7.6	PIK3CA, KIT, VIM, BRCA1, BCL2L1, MUC16
46	5fluorouracil32	4.0	PIK3CA, KIT, PCNA, RB1, BRCA1, VEGFA
47	actinomycin d32	3.8	PIK3CA, KIT, RB1, SERPINE1, VIM, VEGFA
48	testosterone32 9 18 9	6.6	PIP, PIK3CA, KIT, PCNA, RB1, SERPINE1
49	dexamethasone32 42 34 9 9	7.4	PIK3CA, PCNA, RB1, SERPINE1, VIM, VEGFA
50	cisplatin32 34 9 9	5.3	PIK3CA, PCNA, RB1, BRCA1, BRCA2, VEGFA

Cellular components related to ductal carcinoma in situ according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	nuclear chromatin	GO:000790	10.1	RARA, PAX6, MUC1, MSH6, AR, TP53
2	mitochondrial outer membrane	GO:005741	9.6	PPP2R2B, IFI27, BAX, BCL2L1, BCL2, BNIP3L
3	protein complex	GO:043234	9.5	MDM2, TP53, PTGS2, SYP, PSEN2, MEF2C
4	platelet alpha granule lumen	GO:031093	8.9	TGFB1, THBS1, EGF, SPARC, VEGFA, SERPINE1
5	nucleolus	GO:005730	8.5	ERBB4, TP53, TP63, TERT, PTHLH, COPS5
6	cell surface	GO:009986	8.1	PLAU, PLAUR, ABCB1, TIMP2, TGFB1, CXCR4
7	nucleoplasm	GO:005654	7.6	AKT1, ESR1, ESR2, ERBB4, TP53, TP63
8	extracellular space	GO:005615	6.8	CTSD, SPARC, PTHLH, ERBB3, HSPD1, PLAU
9	cytosol	GO:005829	6.7	KRT5, SRC, CYP19A1, PTK2, PTEN, TP53
10	extracellular region	GO:005576	6.7	ESR2, ERBB4, PTHLH, SPARC, CTSD, PLAU
11	plasma membrane	GO:005886	5.1	PTEN, TNK2, ERBB2, ERBB4, ERBB3, ESR1
12	nucleus	GO:005634	4.3	ERBB4, ERBB2, TP53, TP63, TNK2, PTEN
13	cytoplasm	GO:005737	4.2	PGR, PTGS2, PTEN, TERT, TNK2, TP63

Biological processes related to ductal carcinoma in situ according to GeneDecks:

(show top 50)    (show all 90)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of survival gene product expression	GO:008634	10.5	BNIP3L, BAX, BCL2L1, BNIP3
2	negative regulation of focal adhesion assembly	GO:051895	10.4	THBS1, PTEN, APOD, SRC
3	replicative senescence	GO:090399	10.4	TP53, MME, CDKN2A, CDKN1A, TERT
4	response to estrogen stimulus	GO:043627	10.4	ESR1, SERPINE1, BRCA1, BCL2, CD24, CCND1
5	response to cytokine stimulus	GO:034097	10.3	SPARC, STAT1, TIMP4, PTGS2, BCL2L1, BCL2
6	regulation of mitochondrial membrane permeability	GO:046902	10.3	BNIP3, BCL2L1, TP53, BCL2
7	response to ethanol	GO:045471	10.2	ACTC1, SPARC, CCND1, BCL2, MMP9, GSN
8	induction of apoptosis by intracellular signals	GO:008629	10.2	BNIP3, BCL2, BCL2L1, AKT1, BAX, MSH6
9	extracellular matrix disassembly	GO:022617	10.2	MMP9, MMP14, ENG, TIMP2, MMP13
10	neuron apoptotic process	GO:051402	10.2	TP63, TP53, ERBB3, BAX, BCL2, RB1
11	response to reactive oxygen species	GO:000302	10.1	APOD, SERPINE1, GSTP1, S100A7
12	G1 phase of mitotic cell cycle	GO:000080	10.1	CDKN1A, CDKN2A, E2F1, CCND1, CDKN1B, RB1
13	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:006978	10.1	BRCA1, BRCA2, MUC1, TP53
14	Ras protein signal transduction	GO:007265	10.0	RB1, CCNA2, RASSF1, CDKN1A, CDKN2A, SRC
15	cellular response to hypoxia	GO:071456	9.9	BNIP3, E2F1, HIF1A, PTGS2, TP53, MDM2
16	male gonad development	GO:008584	9.9	SRD5A1, WT1, KIT, BCL2, BCL2L1, AR
17	response to estradiol stimulus	GO:032355	9.9	TGFB1, CYP19A1, PTGS2, ESR1, MMP9, TFF1
18	positive regulation of nitric oxide biosynthetic process	GO:045429	9.8	ESR1, IFNG, PTGS2, EGFR, AKT1
19	phosphatidylinositol-mediated signaling	GO:048015	9.8	GSN, PIK3CA, PCNA, PTEN, MDM2, ERBB2
20	heart development	GO:007507	9.8	ERBB2, PCNA, MEF2C, FOXC1, ERBB3, ERBB4
21	regulation of cell proliferation	GO:042127	9.8	PTK2, ERBB3, BRCA1, SPARC, ENG, SERPINE1
22	G1/S transition of mitotic cell cycle	GO:000082	9.8	CCNB1, CDKN2A, CDKN1B, BCL2, RB1, E2F1
23	induction of apoptosis	GO:006917	9.6	CDKN1B, TGFB1, BNIP3L, STAT1, THBS1, WT1
24	endothelial cell migration	GO:043542	9.5	CDH13, PIK3CA, PTEN, PTK2, STAT1
25	anti-apoptosis	GO:006916	9.5	THBS1, TERT, AKT1, GSTP1, MUC1, BCL2L1
26	negative regulation of epithelial cell proliferation	GO:050680	9.5	AR, ESR2, MEF2C, TGFB1, PTEN, RB1
27	positive regulation of gene expression	GO:010628	9.5	MEF2C, E2F1, PLAUR, CD44, PAX6, VEGFA
28	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.4	VEGFA, BCL2, PIK3CA, CD44, AKT1, TGFB1
29	positive regulation of MAP kinase activity	GO:043406	9.3	CD24, VEGFA, ERBB2, EGFR, TGFB1, EGF
30	cell cycle arrest	GO:007050	9.2	TP53, CDKN2A, CDKN1A, CDKN1B, IFNG, RASSF1
31	negative regulation of cell growth	GO:030308	9.2	WT1, RB1, BCL2, CDKN1A, CDKN1B, ESR2
32	response to hypoxia	GO:001666	9.2	PSEN2, BNIP3, BCL2, CD24, MMP9, VEGFA
33	mammary gland alveolus development	GO:060749	9.2	CCND1, ERBB4, EGF, AR
34	virus-host interaction	GO:019048	9.2	BNIP3, RB1, VIM, BNIP3L, BAX, CXCR4
35	positive regulation of protein phosphorylation	GO:001934	9.1	AKT1, ENG, CCND1, ERBB4, ERBB2, PTK2
36	epidermal growth factor receptor signaling pathway	GO:007173	8.8	ERBB2, AKT1, SRC, EGF, EGFR, TGFB1
37	angiogenesis	GO:001525	8.7	FGFR2, PIK3CA, SERPINE1, VEGFA, S100A7, APOD
38	cell proliferation	GO:008283	8.7	AR, ERBB4, ERBB2, TP53, PTEN, E2F1
39	peptidyl-tyrosine phosphorylation	GO:018108	8.6	KIT, FGFR2, ERBB4, PTK2, SRC, EGF
40	positive regulation of cell migration	GO:030335	8.5	VEGFA, CDH13, MMP14, EGFR, ERBB4, PTK2
41	platelet activation	GO:030168	8.5	CSK, TGFB1, THBS1, PIK3CA, SERPINE1, VEGFA
42	blood coagulation	GO:007596	8.3	PTK2, CSK, TGFB1, THBS1, EGF, PIK3CA
43	negative regulation of cell proliferation	GO:008285	8.1	PTGS2, PTHLH, WT1, TIMP2, TP53, IGFBP3
44	positive regulation of transcription, DNA-dependent	GO:045893	7.9	BRCA2, BRCA1, TP53, TP63, EGF, HIF1A
45	negative regulation of apoptotic process	GO:043066	7.9	EGFR, VEGFA, THBS1, SERPINE1, CD44, AR
46	response to drug	GO:042493	7.9	CYP19A1, PTGS2, ERBB4, ERBB3, IFNG, BCL2
47	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.9	BRCA1, SERPINE1, RB1, CDKN2A, TP53, VEGFA
48	signal transduction	GO:007165	7.8	ERBB3, ESR2, ESR1, AKT1, AR, S100A9
49	apoptotic process	GO:006915	7.7	TP53, ERBB4, AKT1, IFNG, E2F1, FGFR2
50	positive regulation of cell proliferation	GO:008284	7.0	VEGFA, BIRC5, EGFR, BCL2L1, FGFR2, RARA

Molecular functions related to ductal carcinoma in situ according to GeneDecks:

(show all 21)

id	Name	GO ID	Score	Top Affiliating Genes
1	nitric-oxide synthase regulator activity	GO:030235	10.4	EGFR, ESR1, AKT1
2	BH3 domain binding	GO:051434	10.3	BCL2, BCL2L1, BAX
3	protein phosphatase binding	GO:019903	10.3	CSK, EGFR, ERBB2, CDH1, CDKN1B
4	protease binding	GO:002020	9.9	TP53, BCL2, BRCA2, SERPINE1, KIT
5	fibronectin binding	GO:001968	9.8	THBS1, IGFBP3, MMP9, VEGFA
6	receptor signaling protein tyrosine kinase activity	GO:004716	9.8	EGFR, ERBB2, ERBB4, KIT
7	transmembrane receptor protein tyrosine kinase activity	GO:004714	9.8	EGFR, ERBB2, ERBB4, ERBB3, KIT
8	RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive	GO:001077	9.7	HIF1A, WT1, TP63, TP53, MEF2C
9	transcription factor binding	GO:008134	9.7	E2F1, HIF1A, TP53, AR, FOXC1, CDKN2A
10	transcription regulatory region DNA binding	GO:044212	9.6	HIF1A, WT1, TP63, TP53, ERBB4, MEF2C
11	protein kinase binding	GO:019901	9.6	HIF1A, PTK2, PTEN, TP53, CCND1, CCNA2
12	ubiquitin protein ligase binding	GO:031625	9.5	RB1, BRCA1, PAX6, BCL2, TP53, HIF1A
13	protein tyrosine kinase activity	GO:004713	9.4	CSK, EGFR, SRC, TNK2, ERBB2, ERBB4
14	identical protein binding	GO:042802	9.2	AKT1, ESR1, ERBB2, TP53, TP63, EGFR
15	calcium ion binding	GO:005509	9.0	STAT1, SYP, DST, THBS1, EGF, SPARC
16	sequence-specific DNA binding transcription factor activity	GO:003700	9.0	ESR2, TP53, WT1, HIF1A, STAT1, PGR
17	protein heterodimerization activity	GO:046982	9.0	ERBB3, ERBB2, TP53, EGFR, HIF1A, TGFB1
18	enzyme binding	GO:019899	8.5	AKT1, ESR1, ESR2, TP53, PTEN, PTGS2
19	protein homodimerization activity	GO:042803	8.0	ERBB3, ERBB4, TERT, PTGS2, DST, TGFB1
20	ATP binding	GO:005524	7.2	TP53, TNK2, PTK2, SRC, EGFR, ABCB1
21	protein binding	GO:005515	0.6	ESR1, PLAUR, COPS5, WT1, KRT5, KRT19